VARUBI

Peak

rolapitant

NDAORALTABLET
Approved
Sep 2015
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
1

Clinical Trials (1)

NCT00539721Phase 2Completed

A Randomized Controlled Study of Rolapitant for the Prevention of Nausea and Vomiting Following Surgery (Study P04937AM1)(COMPLETED)

Started Oct 2007
619 enrolled
Postoperative Nausea and Vomiting

Loss of Exclusivity

LOE Date
Oct 9, 2029
43 months away
Patent Expiry
Oct 9, 2029

Patent Records (5)

Patent #ExpiryTypeUse Code
8178550
Apr 4, 2027
SubstanceProduct
7563801
Apr 4, 2027
Product
7981905
Apr 4, 2027
U-1741
8404702
Apr 4, 2027
U-1741
7049320
Aug 19, 2028
SubstanceProduct
U-1741